Patent classifications
C07D239/78
BROMODOMAIN INHIBITORS
The invention relates to compounds according to the general formula (1), and to the use thereof for production of a medicament, especially for treatment of a disorder associated with bromodomains, such as cancer.
BROMODOMAIN INHIBITORS
The invention relates to compounds according to the general formula (1), and to the use thereof for production of a medicament, especially for treatment of a disorder associated with bromodomains, such as cancer.
Compounds and compositions for treating fibrosis
The present invention provides compounds and methods for treating, ameliorating, and/or preventing a MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
Compounds and compositions for treating fibrosis
The present invention provides compounds and methods for treating, ameliorating, and/or preventing a MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1
The invention relates generally to novel EPAC1 activators, such as Formula I and II and the preparation thereof as well as the use of EPAC1 activators disclosed herein as to selectively activate EPAC1 in cells.
##STR00001##
##STR00002##
SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1
The invention relates generally to novel EPAC1 activators, such as Formula I and II and the preparation thereof as well as the use of EPAC1 activators disclosed herein as to selectively activate EPAC1 in cells.
##STR00001##
##STR00002##
Compounds and Compositions for Treating Fibrosis
The present invention provides compounds and methods for treating MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
Compounds and Compositions for Treating Fibrosis
The present invention provides compounds and methods for treating MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS
The present invention relates to the use of at least one compound of formula (I), or one of its pharmaceutically acceptable salts, for preventing and/or treating a disease caused by a nonsense mutation. It also relates to compounds of formula (II) and their uses.
Preparation method for morpholinquinazoline compound and intermediates thereof
The present disclosure relates to a preparation method morpholinquinazoline compound and a midbody thereof. The preparation method for morpholinquinazoline compound comprises the following steps: S1, performing a Suzuki reaction of compound S and compound IV as represented by the following formula, so as to obtain compound V; step S2, performing a reaction of methylsufonyl chloride and compound V in an organic solvent as represented by the following formula, so as to obtain compound VI; and S3, performing a coupled reaction of compound VII and compound VI in a solvent as represented by the following formula, so as to obtain compound YY-20394. The preparation method has the advantages of higher yield, better selectivity, simple operation and mild reaction condition, and is applicable to industrial production. ##STR00001##